Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK2 | P24941 | 14/20 | 0.92 |
| ▸ | CDK9 | P50750 | 13/20 | 0.92 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.61 |
| ▸ | CDK7 | P50613 | 5/20 | 0.53 |
| ▸ | CCNH | P51946 | 5/20 | 0.53 |
| ▸ | MNAT1 | P51948 | 5/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29842037 | 0.96 | CDK2 (1.00) | CDK2CDK9CCNE1CDK7CCNH | |
| SCHEMBL18050991 | 0.96 | CDK2 (1.00) | CDK2CDK9CCNE1CDK7CCNH | |
| SCHEMBL19912790 | 0.90 | CDK2 (0.78) | CDK2CDK9CCNE1CDK7CCNH | |
| SCHEMBL19912788 | 0.89 | CDK2 (0.84) | CDK2CDK9CCNE1CDK7CCNH | |
| SCHEMBL19912791 | 0.87 | CDK2 (0.81) | CDK2CDK9CCNE1CDK7CCNH | |
| SCHEMBL19912793 | 0.86 | CDK2 (0.77) | CDK2CDK9CCNE1CDK7CCNH | |
| SCHEMBL18050987 | 0.86 | CDK2 (0.81) | CDK2CDK9CCNE1CDK7CCNH | |
| SCHEMBL21741853 | 0.85 | CDK2 (1.00) | CDK2CDK9CCNE1CDK7CCNH | |
| SCHEMBL15238162 | 0.85 | CDK2 (1.00) | CDK2CDK9CCNE1CDK7CCNH | |
| SCHEMBL15241386 | 0.85 | CDK2 (0.80) | CDK2CDK9CCNE1CDK7CCNH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11186576-B2 | Pyrazolo[1,5-A][1,3,5]triazine and pyrazolo[1,5-A]pyrimidine derivatives as CDK inhibitors | AURIGENE DISCOVERY TECHNOLOGIES LIMITED (IN) | 2021-11-30 | — | — | US | disclosed |
| US-20180057497-A1 | Pyrazolo[1,5-A][1,3,5]Triazine and Pyrazolo[1,5-A]Pyrimidine Derivatives as CDK Inhibitors | AURIGENE DISCOVERY TECHNOLOGIES LIMITED (IN) | 2018-03-01 | — | — | US | disclosed |
| US-20180057497-A1 | Pyrazolo[1,5-A][1,3,5]Triazine and Pyrazolo[1,5-A]Pyrimidine Derivatives as CDK Inhibitors | AURIGENE DISCOVERY TECHNOLOGIES LIMITED (IN) | 2018-03-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180057497-A1 | Pyrazolo[1,5-A][1,3,5]Triazine and Pyrazolo[1,5-A]Pyrimidine Derivatives as CDK Inhibitors | CDK15, CDK1, CDK19 | CDK2 13/4885CDK9 8/4885CCNE1 33/4885 |
| US-11186576-B2 | Pyrazolo[1,5-A][1,3,5]triazine and pyrazolo[1,5-A]pyrimidine derivatives as CDK inhibitors | CDK15, CDK1, CDK19 | CDK2 13/4885CDK9 8/4885CCNE1 33/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.